Navigation Links
ALS Therapy Development Institute and Oxford BioMedica Begin Second Phase of Collaboration to Develop Gene Therapies for Amyotrophic Lateral Sclerosis
Date:1/27/2010

l growth factor.  Furthermore, the joint team plans to evaluate other potentially therapeutic genes that inhibit or regulate specific genetic pathways associated with disease onset or progression.

Oxford BioMedica's Chief Executive Officer, John Dawson, commented: "The successful completion of the first phase of the collaboration is testament to the quality of the scientific teams at the ALS TDI and Oxford BioMedica. Our LentiVector technology has unique capabilities to deliver genes safely and efficiently to neuronal cells and our product candidate, MoNuDin, has shown promising results in preclinical models of ALS. The extension of our collaboration with the ALS TDI enables us to accelerate MoNuDin's development and to explore new disease pathways as potential targets for genetic intervention. We are delighted to have ongoing support from the Muscular Dystrophy Association for our collaboration with the ALS TDI, which underscores our shared goal to develop new treatment options for patients suffering from ALS."

The Muscular Dystrophy Association's Augie's Quest Initiative is a major donor to the ALS TDI and provided the critical funding needed to execute the collaboration between Oxford BioMedica and the ALS TDI.

About ALS TDI

The mission of the ALS Therapy Development Institute (ALS TDI) is to develop effective therapeutics that slow or stop amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease), as soon as possible.  Focused on meeting this urgent unmet medical need, ALS TDI executes a robust discovery program, while running the world's largest efforts to pre-clinically validate potential therapeutics; including small molecules, protein biologics, gene therapies and cell-based constructs.  The world's first non-profit biotech, ALS TDI has developed an industrial-scale platform that allows for the development and testing of do
'/>"/>

SOURCE ALS Therapy Development Foundation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
2. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
3. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
4. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
5. Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability
6. Elekta Contract Provides Sisters of Mercy Health System Access to Leading Radiation Therapy Solutions
7. Varian Medical Systems Exhibits Latest Technologies and Products Designed to Improve Speed and Precision of Radiotherapy at ESTRO 2007
8. Elekta Displays Complete Volumetric Intensity Modulated Arc Therapy Solutions at ESTRO
9. Stem Cell Therapy to Skyrocket by 2017
10. Team demos safety of RNA therapy
11. First European IGRT School Takes Place for Radiotherapy Practitioners in UK
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... The  PROPEL Center  of the  iBIO Institute , dedicated ... life sciences companies in Illinois , ... help Illinois entrepreneurs attend ... Chicago .   AdvaMed 2014 is ... , bringing more than 1,000 companies together in ...
(Date:8/1/2014)... August 1, 2014 According to ... "Biophotonics Market - Global Industry Analysis, Size, Share, Growth, ... valued at USD 25.16 billion in 2013, which is ... at a CAGR of 10.4% from 2014 to 2020. ... http://www.transparencymarketresearch.com/biophotonics-market.html Increasing demand for accurate early ...
(Date:8/1/2014)... -- Research and Markets has announced the ... Genotyping and Analysis Market 2014-2018" report to their ... Single Nucleotide Polymorphism (SNP) genotyping is the screening ... genome of various species. SNPs are commonly present in ... can analyze thousands of SNPs and has the potential ...
(Date:8/1/2014)... August 01, 2014 Once a decision ... cost? This webinar will discuss how to define your ... Join speakers Bob Allen, Senior Director of Facilities Integration ... Engineering at Fluor Industrial Services, and special guest Carrier ... Planning at Amgen, as they provide an examination of ...
Breaking Biology Technology:iBIO Institute's PROPEL Center Awards Grants for AdvaMed 2014 to Early-Stage Life Sciences Companies 2iBIO Institute's PROPEL Center Awards Grants for AdvaMed 2014 to Early-Stage Life Sciences Companies 3iBIO Institute's PROPEL Center Awards Grants for AdvaMed 2014 to Early-Stage Life Sciences Companies 4Global Biophotonics Market is Expected to Reach USD 50.20 Billion in 2020: Transparency Market Research 2Global Biophotonics Market is Expected to Reach USD 50.20 Billion in 2020: Transparency Market Research 3Global Biophotonics Market is Expected to Reach USD 50.20 Billion in 2020: Transparency Market Research 4Global Single Nucleotide Polymorphism (SNP) Genotyping and Analysis Market 2014-2018 2Defining Low Cost in Your Solution for Future Facilities, New Webinar for Pharma, Biotech, Medical Device and Healthcare Companies, Hosted by Xtalks 2
... Cord Blood America, Inc . (OTC BB: CBAI, CBAID) announced ... 80 percent of its shareholders voting in a recent proxy vote, ... The one for one hundred reverse split reduces the ... A "D" will be placed on the ticker symbol ...
... BALTIMORE, May 6, 2011 Stenting is safe and ... venous stenosis in patients with deep vein thrombosis (DVT), ... Late-Breaking Clinical Trial at the Society for Cardiovascular Angiography ... EVISTA-DVT focused on patients with blocked veins ...
... Halozyme Therapeutics, Inc. (Nasdaq: HALO ), ... extracellular matrix for the diabetes, cancer, dermatology ... the first quarter 2011. (Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO ... duration of action observed in our first ultrafast insulin ...
Cached Biology Technology:Study Shows Stents Are Superior to Balloons Alone for Patients With Deep Venous Thrombosis 2Halozyme Therapeutics Reports First Quarter 2011 Financial Results 2Halozyme Therapeutics Reports First Quarter 2011 Financial Results 3Halozyme Therapeutics Reports First Quarter 2011 Financial Results 4Halozyme Therapeutics Reports First Quarter 2011 Financial Results 5Halozyme Therapeutics Reports First Quarter 2011 Financial Results 6
(Date:8/1/2014)... cell research will provide enormous opportunities for both ... could replicate any other cells in the body, ... damaged spinal cords, treating kidney, liver and lung ... for profit is staggering. Prof. Jinhui Chen from ... of research still faces myriad biological, ethical, legal, ...
(Date:8/1/2014)... component of phloem, the conductive tissue through which plants ... Elongated cylindrical cells are capped at one end by ... tubes which in turn form a network throughout a ... special cells which play an important role in carbon ... about their differentiation," says Professor Yk Helariutta from the ...
(Date:8/1/2014)... August 1, 2014 The Journal of Nutrition Education ... Best Great Educational Material (GEM) awards, which were presented ... annual conference, "Nutrition Education Impact: Local to Global," in ... These annual awards recognize the authors of the best ... as judged by members of the JNEB Journal Committee ...
Breaking Biology News(10 mins):Developmental regulation of important plant phloem components discovered 2
... the color of ocean waters could have a drastic effect on ... such a change in one region of the North Pacific, the ... be a big drop for a region that accounts for more ... that the formation of typhoons as hurricanes are known in ...
... 13, 2010 -- Ben-Gurion University of the Negev,s (BGU) Dr. ... and Environmental Research Center (BERC) in Nablus received a significant ... the Middle East. This study brings together Israelis and Palestinians ... of Nablus over a five-year period. ...
... RICHLAND, Washington -- A little wax and soap can ... to a study in August 11 issue of ... developers to explore lower-priced alternatives to the lithium ion-metal ... a medium in which to grow good electrode materials," ...
Cached Biology News:Ocean's color affects hurricane paths 2Ocean's color affects hurricane paths 3Wax, soap clean up obstacles to better batteries 2Wax, soap clean up obstacles to better batteries 3Wax, soap clean up obstacles to better batteries 4
Request Info...
... materials necessary for the isolation and preparation of ... Kit Components: Erythrocyte ... containing 220 mL of buffered ammonium chloride. (NH ... No. 5113) One bottle containing 220 mL of ...
... with suspension (non-adherent) cells, RNA ... filtration or centrifugation to separate ... Compatible with 96-well GenePlate®. RiboCap™ ... package sizes and contain the ...
... The Zero Background/Kan Cloning Kit ... kanamycin resistance for selection in ... utilizes positive selection to eliminate ... all of the reagents you ...
Biology Products: